Exelixis, Inc. (EXEL) Stock
EXEL Key Statistics
About Exelixis, Inc.
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
CEO: Michael Morrissey. Company website
EXEL — Frequently Asked Questions
What is the EXEL stock price today?
Exelixis, Inc. (EXEL) trades at $70.70, up 0.17% on the day, as of Nov 12, 2026 09:30 UTC.
What is Exelixis, Inc.'s market cap?
Exelixis, Inc. has a market capitalisation of $17.77B, calculated from the live EXEL share price and shares outstanding.
What is the P/E ratio of EXEL?
EXEL trades at a trailing P/E of 21.14, from earnings per share of $3.34 over the last twelve months.
How much revenue does Exelixis, Inc. make?
Exelixis, Inc. generated revenue of $2.50B over the trailing twelve months, which puts the stock at 7.12 times sales.
What is the 52-week range for EXEL?
EXEL has traded between $39.71 and $73.69 over the past 52 weeks, and the last price is 4.1% below that high.
Is Exelixis, Inc. profitable?
Yes. Exelixis, Inc. keeps 35.45% of revenue as net income over the trailing twelve months.
What is the analyst price target for EXEL?
Wall Street analysts rate EXEL Hold, with an average price target of $53.00, 25.0% below the current price.
What sector is Exelixis, Inc. in?
Exelixis, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Exelixis, Inc.?
Michael Morrissey is the chief executive of Exelixis, Inc., which employs 1,077 people.
Where can I track EXEL in real time?
QFI Terminal shows EXEL with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See EXEL live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open EXEL in Terminal See plans